Baxter (BAX) agrees to pay Onconova Therapeutics $50M upfront for the European commercialization...
Wednesday, September 19, 2012, 9:40 AM ETBaxter (BAX) agrees to pay Onconova Therapeutics $50M upfront for the European commercialization rights for rigosertib, a compound in Phase III trials for treating rare hematologic (blood) malignancies and in Phase II/III trials for pancreatic cancer. Baxter may also pay up to $515M in pre-commercial development and regulatory milestones, as well as sales milestones and royalties. (PR)
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles